Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Redburn Partners Initiates Coverage On Nasdaq with Neutral Rating

Redburn Partners Initiates Coverage On Nasdaq with Neutral Rating

Redburn Partners analyst Michael Cyprys initiates coverage on Nasdaq (NASDAQ:NDAQ) with a Neutral rating.

byBenzinga Newsdesk

November 14, 2022

1 minute read

Redburn Partners analyst Michael Cyprys initiates coverage on Nasdaq (NASDAQ:NDAQ) with a Neutral rating.

Chardan Capital Maintains Buy on Dragonfly Energy Hldgs, Lowers Price Target to $10

By Benzinga Newsdesk

February 10, 9:38 AM

Chardan Capital analyst Brian Dobson maintains Dragonfly Energy Hldgs (NASDAQ:DFLI) with a Buy and lowers the price target from $15 to $10.

DFLI

News

Russia-Controlled Part Of Ukraine’s Zaporizhzhia Region Will Hold Referendum On Joining Russia On Sept 23-27

By Benzinga Newsdesk

September 20, 9:38 AM

- Reuters

RSX

Nuwellis Receives FDA Clearance For An Additional Dual Lumen Extended Length Peripheral Catheter

By Benzinga Newsdesk

January 4, 4:11 PM

Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its

NUWE

SVB Leerink Downgrades Amryt Pharma to Market Perform, Lowers Price Target to $14.5

By Benzinga Newsdesk

January 9, 7:14 AM

SVB Leerink analyst Mani Foroohar downgrades Amryt Pharma (NASDAQ:AMYT) from Outperform to Market Perform and lowers the price target from $19 to $14.5.

AMYT

Redburn Partners Initiates Coverage On Nasdaq with Neutral Rating

Related Posts

Chardan Capital Maintains Buy on Dragonfly Energy Hldgs, Lowers Price Target to $10

Russia-Controlled Part Of Ukraine’s Zaporizhzhia Region Will Hold Referendum On Joining Russia On Sept 23-27

Nuwellis Receives FDA Clearance For An Additional Dual Lumen Extended Length Peripheral Catheter

SVB Leerink Downgrades Amryt Pharma to Market Perform, Lowers Price Target to $14.5